KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aehr Test Systems (AEHR) Cash & Equivalents (2016 - 2025)

Aehr Test Systems (AEHR) has 16 years of Cash & Equivalents data on record, last reported at $30.8 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 4.29% year-over-year to $30.8 million; the TTM value through Nov 2025 reached $30.8 million, down 4.29%, while the annual FY2025 figure was $24.5 million, 50.1% down from the prior year.
  • Cash & Equivalents reached $30.8 million in Q4 2025 per AEHR's latest filing, up from $22.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $51.0 million in Q3 2023 and bottomed at $4.6 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $29.6 million, with a median of $31.2 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: surged 915.69% in 2021, then tumbled 50.1% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $35.0 million in 2021, then plummeted by 46.12% to $18.9 million in 2022, then skyrocketed by 167.64% to $50.5 million in 2023, then tumbled by 36.22% to $32.2 million in 2024, then fell by 4.29% to $30.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $30.8 million in Q4 2025, $22.7 million in Q3 2025, and $24.5 million in Q2 2025.